A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain (AMAZE 5)
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 5)
Sponsor: Novo Nordisk A/S
Listed as NCT07481630, this observational or N/A phase trial focuses on Knee Osteoarthritis (OA) and Obesity and remains actively recruiting participants. Sponsored by Novo Nordisk A/S, it has been updated 2 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
2 versions recorded-
May 4, 2026 — Present [daily]
Recruiting
-
Apr 28, 2026 — May 4, 2026 [daily]
Recruiting
First recorded
Apr 2026
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .